| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| src-Family Kinases | 47 | 2017 | 478 | 6.270 |
Why?
|
| Prostatic Neoplasms | 36 | 2021 | 5767 | 2.520 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 16 | 2014 | 96 | 2.430 |
Why?
|
| Proto-Oncogene Proteins c-met | 10 | 2015 | 419 | 2.040 |
Why?
|
| Bone Neoplasms | 21 | 2021 | 2576 | 1.470 |
Why?
|
| Protein-Tyrosine Kinases | 24 | 2015 | 1756 | 1.410 |
Why?
|
| Colonic Neoplasms | 20 | 2012 | 1390 | 1.390 |
Why?
|
| Cell Movement | 25 | 2018 | 2466 | 1.200 |
Why?
|
| Focal Adhesion Kinase 1 | 5 | 2015 | 111 | 1.140 |
Why?
|
| Adenocarcinoma | 26 | 2015 | 7789 | 1.100 |
Why?
|
| Thiazoles | 13 | 2013 | 726 | 1.100 |
Why?
|
| Colorectal Neoplasms | 19 | 2019 | 3578 | 1.070 |
Why?
|
| Phosphorylation | 42 | 2017 | 4804 | 1.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 21 | 2015 | 1533 | 0.990 |
Why?
|
| Neovascularization, Pathologic | 20 | 2014 | 1547 | 0.990 |
Why?
|
| Pancreatic Neoplasms | 17 | 2011 | 5061 | 0.970 |
Why?
|
| Neoplasm Metastasis | 23 | 2017 | 5112 | 0.960 |
Why?
|
| Antineoplastic Agents | 28 | 2019 | 14289 | 0.940 |
Why?
|
| Mice, Nude | 27 | 2017 | 4307 | 0.930 |
Why?
|
| Receptor, IGF Type 1 | 5 | 2015 | 347 | 0.910 |
Why?
|
| Osteoblasts | 8 | 2020 | 370 | 0.870 |
Why?
|
| Cell Line, Tumor | 53 | 2021 | 14551 | 0.860 |
Why?
|
| Pyrimidines | 18 | 2013 | 3518 | 0.820 |
Why?
|
| Anilides | 5 | 2020 | 268 | 0.810 |
Why?
|
| Proto-Oncogene Proteins c-yes | 7 | 2015 | 23 | 0.810 |
Why?
|
| Tumor Cells, Cultured | 41 | 2020 | 5395 | 0.810 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2013 | 630 | 0.800 |
Why?
|
| Xenograft Model Antitumor Assays | 18 | 2020 | 3821 | 0.800 |
Why?
|
| Signal Transduction | 43 | 2018 | 11965 | 0.790 |
Why?
|
| Genes, src | 4 | 2007 | 27 | 0.770 |
Why?
|
| Interleukin-8 | 5 | 2012 | 519 | 0.770 |
Why?
|
| Protein Kinase Inhibitors | 15 | 2015 | 4757 | 0.770 |
Why?
|
| Organoplatinum Compounds | 5 | 2017 | 702 | 0.760 |
Why?
|
| Receptors, Cell Surface | 9 | 2006 | 862 | 0.760 |
Why?
|
| Cell Cycle Proteins | 6 | 2017 | 2045 | 0.740 |
Why?
|
| Mice | 69 | 2021 | 34495 | 0.730 |
Why?
|
| Transfection | 18 | 2015 | 2944 | 0.720 |
Why?
|
| Hepatocyte Growth Factor | 6 | 2016 | 142 | 0.720 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 272 | 0.710 |
Why?
|
| Endothelial Growth Factors | 9 | 2002 | 197 | 0.710 |
Why?
|
| Lymphokines | 9 | 2002 | 272 | 0.700 |
Why?
|
| Dasatinib | 14 | 2017 | 862 | 0.700 |
Why?
|
| ErbB Receptors | 17 | 2017 | 2295 | 0.700 |
Why?
|
| Animals | 86 | 2021 | 59536 | 0.700 |
Why?
|
| Enzyme Activation | 19 | 2014 | 1764 | 0.680 |
Why?
|
| Pyridines | 7 | 2020 | 1244 | 0.660 |
Why?
|
| Calcium-Binding Proteins | 5 | 2015 | 545 | 0.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2017 | 8873 | 0.640 |
Why?
|
| RNA, Small Interfering | 16 | 2014 | 2216 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 20 | 2011 | 2488 | 0.630 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 3 | 2015 | 60 | 0.630 |
Why?
|
| Deoxycytidine | 7 | 2012 | 1353 | 0.620 |
Why?
|
| Down-Regulation | 12 | 2015 | 2074 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2015 | 5178 | 0.590 |
Why?
|
| Neoplasm Proteins | 10 | 2018 | 3230 | 0.590 |
Why?
|
| Cell Proliferation | 23 | 2020 | 7226 | 0.580 |
Why?
|
| Cell Adhesion | 13 | 2014 | 1008 | 0.580 |
Why?
|
| Neoplasm Transplantation | 11 | 2014 | 1519 | 0.580 |
Why?
|
| Integrin beta1 | 2 | 2014 | 126 | 0.570 |
Why?
|
| Guanine Nucleotide Exchange Factors | 3 | 2006 | 159 | 0.550 |
Why?
|
| Chitosan | 2 | 2015 | 79 | 0.540 |
Why?
|
| Neoplasms | 14 | 2012 | 15193 | 0.540 |
Why?
|
| Multivesicular Bodies | 1 | 2015 | 6 | 0.530 |
Why?
|
| Humans | 159 | 2021 | 261506 | 0.520 |
Why?
|
| Apoptosis | 21 | 2020 | 7591 | 0.500 |
Why?
|
| Talin | 1 | 2014 | 14 | 0.500 |
Why?
|
| Carcinoma | 9 | 2013 | 2578 | 0.490 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2014 | 34 | 0.490 |
Why?
|
| Lymphatic Metastasis | 8 | 2018 | 4844 | 0.490 |
Why?
|
| Genetic Therapy | 3 | 2015 | 1616 | 0.470 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2009 | 1299 | 0.460 |
Why?
|
| Endothelium, Vascular | 5 | 2017 | 891 | 0.440 |
Why?
|
| Receptor, Insulin | 1 | 2012 | 97 | 0.430 |
Why?
|
| Focal Adhesions | 2 | 2014 | 45 | 0.430 |
Why?
|
| Gene Transfer Techniques | 1 | 2015 | 716 | 0.430 |
Why?
|
| Retinal Dehydrogenase | 2 | 2013 | 91 | 0.420 |
Why?
|
| Bone Diseases | 1 | 2012 | 143 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-akt | 14 | 2012 | 2054 | 0.410 |
Why?
|
| Nanoparticles | 2 | 2015 | 554 | 0.400 |
Why?
|
| Mice, SCID | 13 | 2020 | 1869 | 0.400 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 1439 | 0.400 |
Why?
|
| Phosphoproteins | 5 | 2017 | 1152 | 0.390 |
Why?
|
| Capillary Permeability | 2 | 2008 | 114 | 0.390 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 7 | 2013 | 280 | 0.390 |
Why?
|
| Prostate | 3 | 2018 | 1088 | 0.380 |
Why?
|
| Isoenzymes | 2 | 2011 | 614 | 0.380 |
Why?
|
| Male | 60 | 2021 | 123000 | 0.380 |
Why?
|
| Cadherins | 7 | 2017 | 660 | 0.370 |
Why?
|
| Drug Design | 4 | 2011 | 375 | 0.370 |
Why?
|
| Cell Division | 18 | 2006 | 2489 | 0.360 |
Why?
|
| Proteins | 3 | 2017 | 1963 | 0.360 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2014 | 2359 | 0.360 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2013 | 1489 | 0.360 |
Why?
|
| Epidermal Growth Factor | 9 | 2015 | 423 | 0.360 |
Why?
|
| Ovarian Neoplasms | 11 | 2013 | 4638 | 0.350 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 6 | 2018 | 334 | 0.350 |
Why?
|
| Urokinase-Type Plasminogen Activator | 4 | 2007 | 136 | 0.350 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 7222 | 0.350 |
Why?
|
| Tyrosine | 5 | 2013 | 498 | 0.350 |
Why?
|
| Biomarkers, Tumor | 12 | 2020 | 10331 | 0.350 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 1082 | 0.340 |
Why?
|
| Autophagy | 1 | 2015 | 927 | 0.340 |
Why?
|
| Immunoprecipitation | 7 | 2012 | 591 | 0.340 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2020 | 425 | 0.340 |
Why?
|
| Cytoskeletal Proteins | 3 | 2014 | 492 | 0.340 |
Why?
|
| Drug Discovery | 2 | 2013 | 324 | 0.340 |
Why?
|
| Glycoproteins | 3 | 2011 | 747 | 0.330 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2019 | 12 | 0.330 |
Why?
|
| Neuropilin-1 | 2 | 2005 | 40 | 0.330 |
Why?
|
| Blotting, Western | 11 | 2014 | 3536 | 0.330 |
Why?
|
| Enzyme Inhibitors | 9 | 2007 | 1879 | 0.320 |
Why?
|
| Tumor Microenvironment | 6 | 2021 | 2864 | 0.320 |
Why?
|
| Extracellular Matrix | 4 | 2013 | 554 | 0.320 |
Why?
|
| Microfilament Proteins | 2 | 2007 | 487 | 0.310 |
Why?
|
| Adenosine Triphosphate | 3 | 2006 | 571 | 0.310 |
Why?
|
| Peptide Fragments | 2 | 2004 | 1271 | 0.310 |
Why?
|
| Trans-Activators | 2 | 2005 | 1555 | 0.300 |
Why?
|
| RNA Interference | 5 | 2015 | 1408 | 0.300 |
Why?
|
| Cell Survival | 14 | 2018 | 3045 | 0.300 |
Why?
|
| RNA, Catalytic | 2 | 2003 | 37 | 0.300 |
Why?
|
| Mesoderm | 5 | 2009 | 404 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1443 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2017 | 15862 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2014 | 1823 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 11 | 2015 | 3981 | 0.280 |
Why?
|
| Immunoblotting | 9 | 2007 | 886 | 0.280 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 423 | 0.280 |
Why?
|
| Antigens, CD | 1 | 2011 | 1385 | 0.280 |
Why?
|
| cdc25 Phosphatases | 3 | 2013 | 97 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinases | 8 | 2012 | 639 | 0.280 |
Why?
|
| Cell Differentiation | 8 | 2020 | 4078 | 0.270 |
Why?
|
| STAT3 Transcription Factor | 3 | 2009 | 1121 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 125 | 0.270 |
Why?
|
| Phosphotransferases | 1 | 2005 | 84 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2007 | 259 | 0.260 |
Why?
|
| MAP Kinase Signaling System | 3 | 2007 | 848 | 0.260 |
Why?
|
| Endothelial Cells | 2 | 2008 | 1048 | 0.260 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 66 | 0.260 |
Why?
|
| Peptides | 1 | 2011 | 1479 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 3 | 2013 | 2330 | 0.260 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 243 | 0.260 |
Why?
|
| Transcription, Genetic | 10 | 2013 | 3154 | 0.250 |
Why?
|
| Tumor Burden | 4 | 2015 | 1987 | 0.240 |
Why?
|
| Receptors, Androgen | 5 | 2017 | 878 | 0.240 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2018 | 229 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2007 | 649 | 0.230 |
Why?
|
| Gene Expression | 6 | 2021 | 3570 | 0.230 |
Why?
|
| RNA, Messenger | 14 | 2015 | 6150 | 0.230 |
Why?
|
| Adenoviruses, Human | 1 | 2003 | 181 | 0.230 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 139 | 0.230 |
Why?
|
| Ossification, Heterotopic | 2 | 2015 | 79 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 1993 | 1538 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factors | 9 | 2002 | 212 | 0.220 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 5159 | 0.220 |
Why?
|
| Liver Neoplasms | 8 | 2008 | 4557 | 0.220 |
Why?
|
| Oligonucleotides, Antisense | 3 | 1999 | 248 | 0.220 |
Why?
|
| Oxidative Stress | 1 | 2009 | 1129 | 0.220 |
Why?
|
| Osteolysis | 2 | 2020 | 80 | 0.220 |
Why?
|
| Anoikis | 3 | 2014 | 63 | 0.210 |
Why?
|
| Immunohistochemistry | 13 | 2015 | 7548 | 0.210 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 6 | 2006 | 107 | 0.210 |
Why?
|
| src Homology Domains | 2 | 2002 | 124 | 0.210 |
Why?
|
| Blotting, Northern | 6 | 2007 | 682 | 0.210 |
Why?
|
| MicroRNAs | 1 | 2015 | 2947 | 0.210 |
Why?
|
| Disease Progression | 8 | 2013 | 6682 | 0.210 |
Why?
|
| Epithelium | 3 | 2009 | 720 | 0.210 |
Why?
|
| Oncogene Protein p21(ras) | 2 | 2000 | 47 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2013 | 986 | 0.200 |
Why?
|
| Proteoglycans | 2 | 2018 | 259 | 0.200 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 2 | 2013 | 88 | 0.200 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 3 | 2006 | 24 | 0.200 |
Why?
|
| Taxoids | 4 | 2013 | 967 | 0.200 |
Why?
|
| Up-Regulation | 8 | 2015 | 2450 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2015 | 665 | 0.200 |
Why?
|
| Mice, Inbred C3H | 3 | 2005 | 385 | 0.200 |
Why?
|
| NF-kappa B | 3 | 2009 | 1549 | 0.190 |
Why?
|
| HT29 Cells | 3 | 2009 | 159 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 5 | 2015 | 1077 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2020 | 2326 | 0.190 |
Why?
|
| Genes, ras | 3 | 2000 | 667 | 0.190 |
Why?
|
| Cell Cycle | 5 | 2013 | 2084 | 0.190 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 3343 | 0.180 |
Why?
|
| Adenoviridae | 2 | 2003 | 1459 | 0.180 |
Why?
|
| Fluorouracil | 4 | 2017 | 1944 | 0.180 |
Why?
|
| Radium | 1 | 2021 | 93 | 0.180 |
Why?
|
| Adenoma | 3 | 2013 | 716 | 0.180 |
Why?
|
| Janus Kinase 2 | 2 | 2017 | 679 | 0.180 |
Why?
|
| Luciferases | 3 | 2006 | 445 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2007 | 460 | 0.170 |
Why?
|
| Transcription Factors | 5 | 2017 | 5270 | 0.170 |
Why?
|
| Pyrazoles | 3 | 2012 | 1471 | 0.170 |
Why?
|
| Integrins | 2 | 2013 | 262 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 135 | 0.170 |
Why?
|
| Phenylthiohydantoin | 2 | 2017 | 89 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2013 | 436 | 0.170 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 342 | 0.170 |
Why?
|
| Bone and Bones | 3 | 2018 | 619 | 0.170 |
Why?
|
| X-Ray Microtomography | 2 | 2017 | 141 | 0.170 |
Why?
|
| Hyaluronan Receptors | 2 | 2011 | 249 | 0.160 |
Why?
|
| Rectal Neoplasms | 3 | 1993 | 1202 | 0.160 |
Why?
|
| Exosomes | 2 | 2021 | 253 | 0.160 |
Why?
|
| HEK293 Cells | 4 | 2017 | 1489 | 0.160 |
Why?
|
| Autoradiography | 3 | 2008 | 132 | 0.160 |
Why?
|
| Acetyl Coenzyme A | 1 | 2018 | 23 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2017 | 315 | 0.160 |
Why?
|
| Nerve Growth Factors | 1 | 1998 | 109 | 0.160 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 50 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2009 | 5437 | 0.160 |
Why?
|
| Calcification, Physiologic | 1 | 2017 | 56 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1491 | 0.150 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 411 | 0.150 |
Why?
|
| Flow Cytometry | 5 | 2011 | 3033 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 7 | 2015 | 3101 | 0.150 |
Why?
|
| Protein Binding | 4 | 2014 | 3438 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2018 | 184 | 0.150 |
Why?
|
| Time Factors | 7 | 2015 | 12926 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 1724 | 0.140 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2017 | 53 | 0.140 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 13658 | 0.140 |
Why?
|
| Heterografts | 2 | 2017 | 733 | 0.140 |
Why?
|
| Receptor, ErbB-3 | 1 | 2017 | 122 | 0.140 |
Why?
|
| 3T3 Cells | 2 | 2015 | 355 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Xenopus | 3 | 2013 | 219 | 0.140 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2017 | 112 | 0.140 |
Why?
|
| Osteopontin | 1 | 2016 | 148 | 0.140 |
Why?
|
| Bone Morphogenetic Protein 4 | 2 | 2017 | 101 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 9 | 2017 | 1331 | 0.130 |
Why?
|
| Benzodioxoles | 1 | 2015 | 29 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 5 | 2013 | 4367 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2011 | 1248 | 0.130 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 771 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1301 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2012 | 1678 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 253 | 0.130 |
Why?
|
| Cetuximab | 1 | 2017 | 472 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2011 | 3719 | 0.130 |
Why?
|
| RNA, Long Noncoding | 2 | 2017 | 598 | 0.130 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 3022 | 0.130 |
Why?
|
| DNA-Binding Proteins | 3 | 2017 | 4821 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 70 | 0.130 |
Why?
|
| Muscle Neoplasms | 1 | 2015 | 109 | 0.120 |
Why?
|
| Actins | 3 | 2007 | 608 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2014 | 116 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 6 | 2009 | 3976 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2010 | 1555 | 0.120 |
Why?
|
| Breast Neoplasms | 7 | 2019 | 15694 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 182 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 493 | 0.120 |
Why?
|
| Drug Synergism | 3 | 2017 | 1313 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 1997 | 577 | 0.120 |
Why?
|
| Oncogenes | 4 | 1991 | 673 | 0.120 |
Why?
|
| Retroviridae Proteins | 2 | 2010 | 20 | 0.120 |
Why?
|
| Oocytes | 3 | 2013 | 414 | 0.120 |
Why?
|
| Indoles | 4 | 2013 | 1009 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 543 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 65 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 2315 | 0.120 |
Why?
|
| Ligands | 3 | 2013 | 995 | 0.110 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 103 | 0.110 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2013 | 76 | 0.110 |
Why?
|
| Female | 33 | 2019 | 141928 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 270 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2006 | 798 | 0.110 |
Why?
|
| Snake Venoms | 1 | 2012 | 9 | 0.110 |
Why?
|
| Cell Nucleus | 3 | 2007 | 1620 | 0.110 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 479 | 0.110 |
Why?
|
| Acetamides | 1 | 2013 | 113 | 0.110 |
Why?
|
| Piperazines | 2 | 2017 | 2101 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 97 | 0.110 |
Why?
|
| Ubiquitination | 1 | 2015 | 575 | 0.110 |
Why?
|
| Cytokines | 3 | 2015 | 2809 | 0.110 |
Why?
|
| Quinones | 1 | 1991 | 21 | 0.100 |
Why?
|
| DNA Damage | 2 | 2017 | 1954 | 0.100 |
Why?
|
| Triazines | 1 | 2012 | 117 | 0.100 |
Why?
|
| Proto-Oncogenes | 4 | 1998 | 202 | 0.100 |
Why?
|
| Drug Delivery Systems | 2 | 2008 | 669 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1130 | 0.100 |
Why?
|
| Culture Media, Conditioned | 4 | 2017 | 260 | 0.100 |
Why?
|
| Camptothecin | 1 | 2014 | 517 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 361 | 0.100 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 4849 | 0.100 |
Why?
|
| Carcinogenesis | 1 | 2018 | 1026 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 79 | 0.100 |
Why?
|
| AC133 Antigen | 1 | 2011 | 110 | 0.100 |
Why?
|
| CD24 Antigen | 1 | 2011 | 85 | 0.100 |
Why?
|
| beta Catenin | 2 | 2007 | 688 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 342 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 1143 | 0.100 |
Why?
|
| Proteomics | 2 | 2017 | 1380 | 0.100 |
Why?
|
| Norepinephrine | 2 | 2013 | 272 | 0.100 |
Why?
|
| Virus Release | 1 | 2010 | 12 | 0.100 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2010 | 93 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 153 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2011 | 905 | 0.100 |
Why?
|
| Interleukin-1 | 2 | 2003 | 461 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2012 | 4938 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2010 | 323 | 0.090 |
Why?
|
| Cell Line | 14 | 2015 | 5114 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 1993 | 209 | 0.090 |
Why?
|
| Phenotype | 6 | 2009 | 6295 | 0.090 |
Why?
|
| Insulin | 1 | 2016 | 1454 | 0.090 |
Why?
|
| Quinazolines | 1 | 2015 | 923 | 0.090 |
Why?
|
| Aged | 17 | 2020 | 70117 | 0.090 |
Why?
|
| Prognosis | 8 | 2020 | 21713 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2010 | 79 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 604 | 0.090 |
Why?
|
| Collagen | 2 | 2004 | 752 | 0.090 |
Why?
|
| TYK2 Kinase | 1 | 2009 | 9 | 0.090 |
Why?
|
| Osteogenesis | 1 | 2011 | 271 | 0.090 |
Why?
|
| Receptor, Notch2 | 1 | 2009 | 25 | 0.090 |
Why?
|
| Cell Separation | 1 | 2011 | 612 | 0.090 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2002 | 161 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2001 | 330 | 0.080 |
Why?
|
| Survival Rate | 5 | 2021 | 12221 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2014 | 9180 | 0.080 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2008 | 17 | 0.080 |
Why?
|
| Integrin alpha5beta1 | 1 | 2008 | 12 | 0.080 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 29902 | 0.080 |
Why?
|
| HMGA Proteins | 1 | 2008 | 3 | 0.080 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2008 | 27 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2009 | 348 | 0.080 |
Why?
|
| Melanoma | 2 | 2012 | 5317 | 0.080 |
Why?
|
| Stress Fibers | 1 | 2007 | 15 | 0.080 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 196 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2007 | 231 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2014 | 1011 | 0.080 |
Why?
|
| Plasmids | 4 | 2006 | 837 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2010 | 413 | 0.080 |
Why?
|
| Random Allocation | 1 | 2009 | 703 | 0.080 |
Why?
|
| Fibroblasts | 4 | 2008 | 1682 | 0.080 |
Why?
|
| Cell Communication | 3 | 2017 | 509 | 0.070 |
Why?
|
| Tetrazolium Salts | 1 | 2007 | 54 | 0.070 |
Why?
|
| Middle Aged | 16 | 2020 | 86204 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1165 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2013 | 1823 | 0.070 |
Why?
|
| Kinetics | 4 | 1997 | 2049 | 0.070 |
Why?
|
| Lysophospholipids | 1 | 2007 | 147 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 1399 | 0.070 |
Why?
|
| Gene Expression Regulation | 6 | 2001 | 4053 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2017 | 1290 | 0.070 |
Why?
|
| Xenopus Proteins | 1 | 2007 | 185 | 0.070 |
Why?
|
| Meiosis | 1 | 2007 | 166 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2007 | 195 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 107 | 0.070 |
Why?
|
| Nitriles | 3 | 2017 | 906 | 0.070 |
Why?
|
| Cytoskeleton | 2 | 2006 | 267 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2015 | 32848 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 448 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 697 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 153 | 0.070 |
Why?
|
| Semaphorin-3A | 1 | 2005 | 2 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2011 | 157 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2006 | 95 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1986 | 185 | 0.070 |
Why?
|
| Receptor, EphA2 | 1 | 2006 | 132 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 1283 | 0.070 |
Why?
|
| Trisomy | 1 | 1986 | 231 | 0.070 |
Why?
|
| Cobalt | 1 | 2005 | 55 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2002 | 1064 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2005 | 117 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 461 | 0.060 |
Why?
|
| SEER Program | 2 | 2019 | 1000 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 1350 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2015 | 4975 | 0.060 |
Why?
|
| Doxycycline | 1 | 2005 | 178 | 0.060 |
Why?
|
| Clone Cells | 4 | 2006 | 555 | 0.060 |
Why?
|
| G1 Phase | 1 | 2005 | 285 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2008 | 406 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 2 | 2005 | 2518 | 0.060 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2004 | 42 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 987 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2015 | 2341 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 663 | 0.060 |
Why?
|
| Recombinant Proteins | 5 | 2011 | 2927 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1546 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 518 | 0.060 |
Why?
|
| Threonine | 1 | 2004 | 161 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2018 | 10001 | 0.060 |
Why?
|
| Regression Analysis | 2 | 1997 | 1546 | 0.060 |
Why?
|
| Medicare | 2 | 2019 | 860 | 0.060 |
Why?
|
| Laminin | 1 | 2004 | 194 | 0.060 |
Why?
|
| Osteoclasts | 1 | 2004 | 165 | 0.060 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2003 | 45 | 0.060 |
Why?
|
| Enzyme Precursors | 1 | 2003 | 66 | 0.060 |
Why?
|
| NIH 3T3 Cells | 2 | 2017 | 260 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2005 | 376 | 0.060 |
Why?
|
| Interleukins | 1 | 2005 | 325 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2003 | 113 | 0.060 |
Why?
|
| Mutation | 7 | 2013 | 15179 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1038 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 1 | 2003 | 249 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2004 | 177 | 0.050 |
Why?
|
| Precipitin Tests | 2 | 1993 | 329 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 215 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.050 |
Why?
|
| Paxillin | 1 | 2002 | 30 | 0.050 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1993 | 95 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2005 | 1070 | 0.050 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 139 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 769 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2009 | 2819 | 0.050 |
Why?
|
| Hypoxia | 1 | 2005 | 443 | 0.050 |
Why?
|
| Cells, Cultured | 5 | 2017 | 5637 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1866 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 1998 | 1694 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2004 | 621 | 0.050 |
Why?
|
| Benzamides | 3 | 2017 | 1832 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 588 | 0.050 |
Why?
|
| Mucins | 2 | 1993 | 285 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2004 | 336 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 750 | 0.050 |
Why?
|
| Stress, Mechanical | 1 | 2002 | 311 | 0.050 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 4233 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2000 | 394 | 0.050 |
Why?
|
| RNA | 2 | 2021 | 1013 | 0.050 |
Why?
|
| Tea | 1 | 2001 | 43 | 0.050 |
Why?
|
| Catechin | 1 | 2001 | 32 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 2265 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2002 | 271 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 14889 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 1999 | 153 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2001 | 157 | 0.050 |
Why?
|
| Models, Biological | 4 | 2005 | 3254 | 0.050 |
Why?
|
| DNA Replication | 2 | 2017 | 744 | 0.050 |
Why?
|
| Base Sequence | 2 | 2005 | 4917 | 0.050 |
Why?
|
| Lung Neoplasms | 7 | 2010 | 11538 | 0.050 |
Why?
|
| Paracrine Communication | 1 | 2001 | 128 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2003 | 576 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2011 | 650 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3890 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 2013 | 6089 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3639 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 1992 | 221 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 4143 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 803 | 0.050 |
Why?
|
| p21-Activated Kinases | 1 | 2000 | 122 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2014 | 1062 | 0.040 |
Why?
|
| DNA, Neoplasm | 3 | 2006 | 1910 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 2508 | 0.040 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 1998 | 14 | 0.040 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1998 | 31 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2020 | 626 | 0.040 |
Why?
|
| Inflammation | 1 | 2008 | 2522 | 0.040 |
Why?
|
| Carnitine O-Acetyltransferase | 1 | 2018 | 6 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 1 | 1999 | 188 | 0.040 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2018 | 11 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 3 | 2007 | 1487 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 1999 | 170 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2006 | 2022 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2018 | 57 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 124 | 0.040 |
Why?
|
| Protein Kinases | 4 | 2005 | 874 | 0.040 |
Why?
|
| DNA, Antisense | 1 | 1997 | 42 | 0.040 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 4654 | 0.040 |
Why?
|
| Gene Amplification | 2 | 1993 | 731 | 0.040 |
Why?
|
| U937 Cells | 1 | 2017 | 171 | 0.040 |
Why?
|
| Fibronectins | 2 | 2008 | 197 | 0.040 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 41 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 2 | 2011 | 993 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 1618 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2003 | 1094 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 164 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2018 | 171 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 328 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 276 | 0.040 |
Why?
|
| Patient Selection | 1 | 2004 | 2055 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 332 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2017 | 185 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 717 | 0.030 |
Why?
|
| Catechols | 1 | 1995 | 14 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 1990 | 494 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2003 | 703 | 0.030 |
Why?
|
| Thiophenes | 1 | 2017 | 148 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 550 | 0.030 |
Why?
|
| Tyrphostins | 1 | 1995 | 107 | 0.030 |
Why?
|
| Urea | 1 | 2017 | 290 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 324 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 278 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 2 | 1993 | 115 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 702 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2018 | 448 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2017 | 430 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 323 | 0.030 |
Why?
|
| Microtubules | 2 | 2013 | 270 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2007 | 652 | 0.030 |
Why?
|
| Wheat Germ Agglutinins | 1 | 1993 | 17 | 0.030 |
Why?
|
| Adult | 7 | 2017 | 77950 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 2010 | 549 | 0.030 |
Why?
|
| Staphylococcal Protein A | 1 | 1993 | 18 | 0.030 |
Why?
|
| Gene Products, gag | 2 | 2010 | 36 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 2 | 1991 | 31 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 2013 | 135 | 0.030 |
Why?
|
| Mucin-1 | 1 | 1993 | 127 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 108 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 289 | 0.030 |
Why?
|
| Pyrroles | 2 | 2011 | 576 | 0.030 |
Why?
|
| Enzyme Induction | 2 | 1991 | 249 | 0.030 |
Why?
|
| Cell Transformation, Viral | 3 | 1988 | 138 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2013 | 107 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2139 | 0.030 |
Why?
|
| Genes, APC | 1 | 1992 | 70 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1993 | 87 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2013 | 240 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 521 | 0.030 |
Why?
|
| Tubulin | 3 | 1988 | 169 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1992 | 222 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 234 | 0.030 |
Why?
|
| Rifabutin | 1 | 1991 | 25 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 289 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 269 | 0.030 |
Why?
|
| Androstenols | 1 | 2011 | 10 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2013 | 358 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1993 | 371 | 0.030 |
Why?
|
| Clusterin | 1 | 2011 | 28 | 0.030 |
Why?
|
| Androstenes | 1 | 2011 | 41 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1742 | 0.030 |
Why?
|
| Cell Count | 1 | 2012 | 508 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 2011 | 60 | 0.030 |
Why?
|
| Tissue Extracts | 1 | 2011 | 48 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 1 | 1991 | 90 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 2352 | 0.030 |
Why?
|
| Castration | 1 | 2011 | 122 | 0.030 |
Why?
|
| Benzoquinones | 1 | 1991 | 108 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2011 | 74 | 0.020 |
Why?
|
| Infectious Anemia Virus, Equine | 1 | 2010 | 5 | 0.020 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2010 | 17 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 435 | 0.020 |
Why?
|
| Proline-Rich Protein Domains | 1 | 2010 | 7 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2011 | 84 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2011 | 62 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2011 | 113 | 0.020 |
Why?
|
| Denosumab | 1 | 2011 | 68 | 0.020 |
Why?
|
| Macrophages | 2 | 1988 | 1304 | 0.020 |
Why?
|
| Endopeptidases | 1 | 1992 | 220 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 597 | 0.020 |
Why?
|
| United States | 2 | 2019 | 15433 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 2527 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 104 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 214 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 1993 | 1073 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1992 | 557 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2011 | 119 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2014 | 825 | 0.020 |
Why?
|
| Genes, myc | 1 | 1992 | 358 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 85 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2010 | 59 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2010 | 189 | 0.020 |
Why?
|
| Reference Values | 1 | 1993 | 1099 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1991 | 223 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2010 | 850 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2010 | 142 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 323 | 0.020 |
Why?
|
| Mass Screening | 1 | 2019 | 1509 | 0.020 |
Why?
|
| Osteonectin | 1 | 2010 | 53 | 0.020 |
Why?
|
| Intercellular Junctions | 1 | 1990 | 54 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2010 | 176 | 0.020 |
Why?
|
| Rectum | 1 | 1992 | 467 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 4988 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2010 | 182 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Amino Acids | 2 | 2010 | 728 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 234 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 3 | 2003 | 2314 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 2083 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 3552 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2010 | 135 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2010 | 280 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2013 | 518 | 0.020 |
Why?
|
| Receptor, Notch4 | 1 | 2009 | 13 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 584 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 492 | 0.020 |
Why?
|
| Mopidamol | 1 | 1988 | 1 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2009 | 85 | 0.020 |
Why?
|
| DNA Repair | 1 | 2017 | 1872 | 0.020 |
Why?
|
| Tretinoin | 1 | 1992 | 623 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2009 | 101 | 0.020 |
Why?
|
| Lymphoma | 2 | 1988 | 1467 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 666 | 0.020 |
Why?
|
| Vitronectin | 1 | 2008 | 22 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 1992 | 487 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2009 | 159 | 0.020 |
Why?
|
| Colon | 1 | 1992 | 670 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2008 | 45 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 1992 | 533 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 4971 | 0.020 |
Why?
|
| Caspases | 1 | 2011 | 661 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4314 | 0.020 |
Why?
|
| Cell Shape | 1 | 2008 | 128 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 5710 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 1391 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1991 | 726 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1989 | 587 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 607 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 1732 | 0.020 |
Why?
|
| Phospholipase D | 1 | 2007 | 26 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 938 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2008 | 138 | 0.020 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2007 | 80 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 2007 | 153 | 0.020 |
Why?
|
| Interphase | 1 | 2007 | 145 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2007 | 392 | 0.020 |
Why?
|
| Potassium | 1 | 1988 | 329 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2011 | 710 | 0.020 |
Why?
|
| Metformin | 1 | 2010 | 378 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1993 | 1081 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1053 | 0.020 |
Why?
|
| Retroviridae | 1 | 1987 | 332 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 2588 | 0.020 |
Why?
|
| Edetic Acid | 1 | 2006 | 73 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 1149 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 586 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 840 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 597 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2006 | 220 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2009 | 383 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 5047 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 359 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 844 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2005 | 132 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2005 | 131 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1989 | 810 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1988 | 518 | 0.020 |
Why?
|
| Karyotyping | 1 | 1986 | 1022 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 37905 | 0.020 |
Why?
|
| Mitosis | 1 | 2007 | 615 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1037 | 0.020 |
Why?
|
| Blast Crisis | 2 | 2003 | 557 | 0.010 |
Why?
|
| Sarcoma Viruses, Murine | 1 | 1983 | 12 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1986 | 408 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2006 | 584 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1983 | 202 | 0.010 |
Why?
|
| Philadelphia Chromosome | 1 | 1987 | 793 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1988 | 904 | 0.010 |
Why?
|
| K562 Cells | 1 | 2003 | 338 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2307 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2003 | 189 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1987 | 941 | 0.010 |
Why?
|
| Molecular Weight | 3 | 1987 | 629 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 2432 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 1818 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6207 | 0.010 |
Why?
|
| Propionates | 1 | 2001 | 71 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2001 | 80 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 483 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 17523 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 12873 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1983 | 435 | 0.010 |
Why?
|
| Androstadienes | 1 | 2001 | 165 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 3203 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 3251 | 0.010 |
Why?
|
| Rats | 4 | 1992 | 6086 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1999 | 74 | 0.010 |
Why?
|
| Peptide Library | 1 | 1999 | 158 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 568 | 0.010 |
Why?
|
| Flavonoids | 1 | 1999 | 188 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2003 | 1665 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 301 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2011 | 3341 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1999 | 503 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1988 | 2138 | 0.010 |
Why?
|
| Immunosorbent Techniques | 2 | 1986 | 57 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1995 | 149 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 661 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2001 | 787 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 3151 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 999 | 0.010 |
Why?
|
| Glioma | 1 | 1986 | 1963 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1992 | 5319 | 0.010 |
Why?
|
| Temperature | 2 | 1988 | 506 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 21445 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 931 | 0.010 |
Why?
|
| Alkaloids | 1 | 1993 | 75 | 0.010 |
Why?
|
| Staurosporine | 1 | 1993 | 143 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 406 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1995 | 624 | 0.010 |
Why?
|
| Suramin | 1 | 1992 | 14 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1992 | 54 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1992 | 224 | 0.010 |
Why?
|
| Glycosylation | 1 | 1992 | 213 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 1213 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1990 | 218 | 0.010 |
Why?
|
| Teratoma | 1 | 1991 | 236 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1988 | 61 | 0.010 |
Why?
|
| Immunologic Surveillance | 1 | 1988 | 60 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1988 | 334 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1988 | 220 | 0.000 |
Why?
|
| Macrophage Activation | 1 | 1988 | 148 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1988 | 234 | 0.000 |
Why?
|
| Poly I-C | 1 | 1987 | 29 | 0.000 |
Why?
|
| Keratins | 1 | 1988 | 330 | 0.000 |
Why?
|
| Phosphotyrosine | 1 | 1987 | 111 | 0.000 |
Why?
|
| Peptide Mapping | 1 | 1987 | 114 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1993 | 1203 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1988 | 402 | 0.000 |
Why?
|
| Collodion | 1 | 1986 | 16 | 0.000 |
Why?
|
| Immunologic Tests | 1 | 1986 | 33 | 0.000 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1988 | 675 | 0.000 |
Why?
|
| Viral Envelope Proteins | 1 | 1987 | 207 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1988 | 974 | 0.000 |
Why?
|
| Neuroglia | 1 | 1986 | 223 | 0.000 |
Why?
|
| Receptors, Progesterone | 1 | 1988 | 1392 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1988 | 1960 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1983 | 671 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1988 | 2086 | 0.000 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1989 | 1833 | 0.000 |
Why?
|